Granules India Q1 FY27: PAT up 60%, revenue +22%

Strongest first quarter on record

Granules India Ltd (NSE: GRANULES) reported what management described as its strongest first quarter ever in Q1 FY27. The company’s growth was supported by a shift toward complex generics and higher-value products, alongside steady scaling in its peptide CDMO platform. Consolidated revenue rose 22% year-on-year to ₹1,476.8 crore. Profit growth outpaced sales, with margins staying firm through the quarter. The company also highlighted improved capital efficiency and a sharp reduction in leverage. Alongside the results, Granules filed a regulatory disclosure confirming that the Q1 FY27 earnings call recording has been uploaded to its website.

Key financial highlights: revenue, margins, and profit

For Q1 FY27, Granules reported gross margin of 65.6%, described as healthy and wider year-on-year by 74 basis points. EBITDA increased 37% year-on-year to ₹338.9 crore, and the EBITDA margin stood at 22.9%, up 256 basis points year-on-year. Profit after tax (PAT) climbed 60% to ₹180 crore, reflecting stronger operating performance. The company also reported profit before tax (PBT) of ₹240.4 crore, up 66.4% from ₹144.5 crore in Q1 FY26. Basic and diluted EPS (consolidated) for the quarter were ₹7.26 and ₹7.12, respectively.

Product mix shift toward complex generics

Management attributed part of the margin profile to an improving mix in finished dosages. Complex generics were reported to comprise 50% of finished dosages, up from 39% a year ago. The company indicated that growth in finished dosages was supported by complex generics, with contributions from North America and Europe. This mix change was cited as one driver for margin expansion and stronger profitability. The commentary in the earnings material framed this as part of the company’s move to higher-value products. Granules also noted that the peptide CDMO platform continued to scale steadily.

Cash flow, debt reduction, and capital efficiency

Granules reported operating cash flow of ₹387.4 crore for Q1 FY27. It also disclosed that net debt stood at ₹101.2 crore, down from ₹402.1 crore at the FY26 close. Return on capital employed (ROCE) improved to 18%. On leverage, the company’s materials included two reported figures: net debt/EBITDA at 0.37x in a summary line, and net debt/EBITDA at 0.07x in the detailed financial highlights and management commentary describing the ratio as “almost nothing.” In both descriptions, the message was that leverage is now very low.

R&D spending and capex in Q1 FY27

The company disclosed R&D expenses of ₹88 crore, about 6% of sales, and up 30% year-on-year. This level of R&D spending was positioned as part of its push in complex products and platform expansion. Granules also reported capex of ₹89 crore during the quarter. In addition, net working capital to sales was reported at 29%. These data points give a clearer picture of how much the company is reinvesting while still generating operating cash.

Regulatory update: Gagillapur remediation and FDA-related launches

Granules’ earnings summary noted that remediation work at the Gagillapur plant is essentially complete. Management also said there are nine launches waiting on FDA clearance. Separately, the company’s summary noted that seven of eight facilities carry a clean EIR, while the USFDA warning letter remains a risk. These statements were presented as part of the broader operational and regulatory context for the quarter. The company did not provide a specific timeline for clearance in the provided text.

Standalone numbers disclosed alongside consolidated results

Alongside consolidated performance, Granules reported standalone figures for Q1 FY27. Standalone revenue was ₹801.9 crore, and standalone net profit was ₹71.7 crore. These numbers provide an additional lens into performance excluding subsidiaries and consolidated adjustments. The company also noted that the Q1 FY27 financial statements were approved and prepared in accordance with Ind AS and SEBI regulations.

Conference call recording: regulatory disclosure and access

Granules submitted a disclosure to the NSE and BSE under Regulation 46 of SEBI (LODR), 2015 regarding the earnings call recording. The company stated that the audio recording of the Q1 FY27 earnings conference call has been uploaded to its official website. The link provided in the disclosure is:

https://granulesindia.com/investors/investor-resources/earnings-call-recording/

The disclosure date and earnings call date referenced in the provided material is July 21, 2026.

Summary table: Q1 FY27 snapshot

What investors are likely to track next

The results highlight a quarter where profitability improved faster than revenue, supported by mix and margins. Investors are likely to monitor how quickly FDA clearances progress for the launches mentioned by management and whether the regulatory overhang around the warning letter changes. The trajectory of the peptide CDMO platform also remains relevant, especially since the earnings summary noted an EBITDA loss for the platform in Q1 FY27 even as revenues grew over 100% year-on-year. In the near term, the company’s low net debt position and operating cash flow are key balance-sheet indicators to watch. Any updates from the company on regulatory milestones or launch timing would add more clarity to forward execution.

Conclusion

Granules India’s Q1 FY27 performance combined 22% revenue growth, margin expansion, and a 60% rise in PAT. The quarter also showed strong operating cash generation and materially lower net debt. The company has made the Q1 FY27 earnings call recording available on its website following a SEBI LODR disclosure, and the market will watch for further updates on FDA-related launch clearances and ongoing regulatory status.